Congressman Burlison joins the Morning Newswatch to discuss Epstein, healthcare

Missouri Congressman Eric Burlison appeared on KZRG's Morning Newswatch for his regular spot on Friday offering insights into the ongoing House Oversight Committee investigation into Jeffrey Epstein's finances and connections, as well as his views on prescription drug pricing reforms under the Trump administration.

During the interview, Burlison, a member of the Oversight Committee, discussed the recent closed-door deposition of Richard Kahn, Jeffrey Epstein's longtime accountant and co-executor of his estate. Kahn testified on March 11, providing details on Epstein's major clients and financial operations.

Burlison explained that Kahn identified Epstein's primary clients as including Leslie Wexner, Glenn Dubin, Steven Sinofsky, the Rothschild family, and Leon Black. He described Epstein as functioning primarily as a "tax consultant and financial advisor" who "moved a lot of money around" for these high-profile figures.

The congressman highlighted the investigative value of following the financial trail. "That's where we can kind of validate some of the claims that have been made," Burlison said, noting that discrepancies between prior depositions—such as Leslie Wexner's—and financial records could lead to further scrutiny.

Switching topics, the discussion turned to healthcare and the Trump administration's TrumpRx initiative, launched earlier in 2026 via TrumpRx.gov. The platform aims to provide transparency on prescription drug prices by displaying "most-favored-nation" (MFN) pricing—aligning U.S. costs with the lowest paid in other developed countries—and offering discounts or coupons for certain medications.

Burlison described TrumpRx as a tool for price comparison, citing examples like Ozempic dropping from around $1,000 per month to about $350 or lower in some cases. He praised the transparency but cautioned that it alone is insufficient in a non-free market where consumers lack real choice.

"It's a good thing. It just isn't... it just will create more frustration without giving people the freedom to choose," Burlison said, likening it to knowing gas prices are higher at one station but being forced to use only that one.

He advocated for broader reforms through his proposed MAHA Act (Make America Healthy Again Act), which would empower individuals by directing healthcare dollars—whether from employers, pre-tax contributions, or government aid—into personal accounts controlled by patients. This, he argued, would enable true market competition in insurance and care.

"Once the American consumer has the money in their hands... the market will naturally start being transparent on prices," Burlison explained. He compared it to everyday shopping: patients would reject poor-performing insurers or providers, much like walking out of a restaurant with no prices listed.

Burlison stressed that combining price transparency with consumer control of funds would amplify savings and accountability, making initiatives like TrumpRx more effective.

The interview concluded amicably, with the hosts thanking Burlison for his time and insights on these high-profile issues. The full conversation aired live from the Downstream Casino Resort Studio on News Talk KZRG.